What would be your approach to a patient with a PIK3CA mutation after progressing on multiple lines of chemotherapy, immunotherapy and PARPi for gBRCA mutated metastatic TNBC?

Would recommend the patient go on a clinical trial of inhibitors against PI3K or AR. Mutations in PIK3CA occurs in approximately 7-9% in TNBC. AR pos TNBC has a higher likelihood of PIK3CA mutation. In the LOTUS trial, the addition of ipatasertib (AKT inhibitor) to paclitaxel improved PFS in patient...